Nintedanib (BIBF 1120) in Mesothelioma
Terminated
This is a phase II/III confirmatory study designed to evaluate the safety and efficacy of nintedanib (BIBF 1120) in combination + (pemetrexed / cisplatin) followed by nintedanib (BIBF 1120) versus placebo + pemetrexed / cisplatin followed by placebo for the treatment of patients with unresectable malignant pleural mesothelioma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/15/2019
Locations: Comprehensive Cancer Centers of Nevada, Henderson, Nevada
Conditions: Mesothelioma
PARTNER: Panitumumab Added to Regimen for Treatment of Head aNd Neck Cancer Evaluation of Response
Completed
This is a randomized, open-label, 2-arm, controlled, phase 2, multi-center, estimation clinical trial of docetaxel and cisplatin combination chemotherapy with and without panitumumab in the first-line treatment of subjects with metastatic or recurrent head and neck cancer, as well as a cross-over second-line panitumumab monotherapy of subjects who fail the chemotherapy only arm. This study will be conducted in the United States. Approximately 150 subjects with histologically or cytologically con... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
09/20/2018
Locations: Research Site, Henderson, Nevada
Conditions: Metastatic or Recurrent Squamous Cell Carcinoma of Head and Neck
First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma
Terminated
This is a phase 3, multicenter, randomized, double-blind, placebo controlled study of epirubicin, cisplatin \& capecitabine (ECX) with rilotumumab or placebo for untreated advanced MET-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
01/18/2016
Locations: Research Site, Henderson, Nevada
Conditions: Gastric Cancer